Skip to the content
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact

Partner With Us

Challenging Targets Require Novel Solutions

Rarely is a successful journey from concept to clinic confined to standard methodologies and off-the-shelf solutions. 

That is why Nimble Therapeutics was built to be much more than a technology.

Our highly skilled and passionate team of scientists and engineers provide advanced capabilities that, propelled by our technology, unlock previously inaccessible chemical landscapes to drive discovery. We nurture a collaborative environment and are highly engaged with our partners from day one.

Together with our partners, Nimble Therapeutics is dedicated to transforming these discoveries into novel medicines that positively impact human health.

Integrated Capabilities

Design
Synthesis
Assays
Informatics
Design

Nimble Therapeutics’ proprietary chemical language enables rapid and efficient implementation of design concepts into a set of complete instructions for fully automated, massively parallel library synthesis. These custom-built tools are deeply integrated with our high-precision, fully automated, light-directed chemical synthesis platform.  Together, this enables Nimble to design libraries unique to each target and encompassing a chemical space bounded only by imagination.

Features

  • Bespoke library designs are tailored to the target of interest and its unique attributes.
  • Vast design space reflects flexibility of chemical synthesis platform and encompasses diverse building blocks, chemical bonds, molecules sizes, and compositions
  • Designs draw on deep in-house catalog of >350 chemical building blocks
  • Compatible with Nimble’s proprietary Display-to-Array (D2A) technology

Additional Information & Resources

Explore some design concepts & core implementation of our platform.

Bitmap Copy

Synthesis

Inspired by traditional solid-phase synthesis, Nimble Therapeutics’ proprietary instrumentation represents a sophisticated integration of photolithography, precision optics, fluidics, and automation.  Our platform enables exquisite combinatorial synthesis of tailor-made libraries in a matter of hours from up to hundreds of different monomers, in linear cyclic and branched conformations.

Features

  • Robust, fully automated synthesis of custom libraries with integrated quality controls
  • Solid-phase synthesis leveraging orthogonal and proprietary photo-protection chemistry
  • Seamless integration with Nimble’s custom-built informatics and assays

Additional Information & Resources

Fragment Based Discovery
Protein-Protein Disruptor Discovery
Rapid Phage Single-Step Selection & Step-Wise Array Optimization
Small Branched & Cyclic Peptide Discovery Libraries
Scaffolded alpha helical, beta hairpins Discovery Libraries

synthesis

Assays

Nimble Therapeutics’ veteran team has developed and implemented biological assays for massively parallel screening and optimization of peptides towards molecules with pharmaceutically relevant properties. Our ability to explore and interrogate multiple parameters of molecules in parallel guides downstream modifications harmonized with both the target location and disease.

Features

  • Comprehensive suite of custom assays including:
    • protein-peptide binding,
    • multi-channel competition,
    • enzyme substrate characterization and inhibition, and
    • proteolytic stability
  • Each assay enables efficient characterization of every library member
  • Each assay can be customized to enable tailored characterization of target of interest
EDW112_SC012_Peptide_Interaction_00_06-min

Informatics

Our advanced and proprietary analytical pipeline, integrating bioinformatics, chemoinformatics, and machine learning, is engineered from the ground up to transform massive empirical data sets into actionable insights.  This purpose-built informatics platform is applied to both de novo library design and subsequent characterization of the resulting empirical data.  This process informs creation of the next bespoke library, and fuels a rapid, highly iterative approach to engineering peptides optimized for multiple characteristics in parallel.

Features

  • Data analytics for robust evaluation of structure activity relationships (SAR) independent of crystallography
  • Analysis of extensive empirical data informs multi-parameter optimization of pharmaceutical properties
  • Purpose built informatics pipeline, leveraging a variety of chemical descriptors, aids navigation of vast chemical space and informs design of subsequent libraries
Nimble Screen 1_4.1.1-min

OPTIONAL Related Documentation Title Here View PDF

Ready to Partner with Nimble?

This strategic partnership enables us to broaden the scope of our programs and develop pioneering therapies that can have a profound impact on the lives of millions.

  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • CONNECT ON LINKEDIN

Copyright © 2024 Nimble Therapeutics, Inc